Crunchyroll, Aniplex and Sony Pictures’ Demon Slayer: Kimetsu no Yaiba Infinity Castle delivered a £3.4 million (€3.9m) box office in its opening weekend, breaking the record for highest earning for ...

‘Bridging the gap between tech and the human body! Researchers have created an artificial plastic neuron that mimics brain-like functions with a single transistor. This breakthrough in #neuromorphic ...

An artificial neuron made of conductive plastics that can perform advanced functions similar to those of biological nerve cells has been demonstrated by researchers at Linköping University, Sweden.

CEO Aaron Levie reported "a strong second quarter with results above our guidance, reflecting continued growth in customer adoption of Box AI and our advanced workflow capabilities." He highlighted ...

SCIB1/iSCIB1+ combined with checkpoint inhibitors shows improved response rates and progression-free survival in advanced melanoma without added toxicity. The SCOPE trial's findings suggest a ...

As the newest and most advanced 2-in-1 vacuum and mop within iRobot's recently introduced suite of new Roomba robots, the Roomba Max 705 Combo conquers everyday messes - every day. At the heart of the ...

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is ...

OpenAI’s ChatGPT is adding new features for business users, including integrations with different cloud services, meeting recordings, and MCP connection support for connecting to tools for deep ...

A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to late-stage trial data published Friday in The New England Journal of Medicine ...

Last week at its virtual Content + AI Summit, Box announced significant AI enhancements to its platform, with the aim of significantly reshaping not only its own capabilities, but perhaps enterprise ...

Samuraciclib, a CDK7 inhibitor, shows promise in HR-positive advanced breast cancer post-CDK4/6 inhibitor therapy, with extended PFS in specific patient groups. MORPHEUS and Module 2A trials highlight ...